TY - JOUR
TI - A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States
AU - Lazaros, G.
AU - Anastassopoulou, C.
AU - Hatziantoniou, S.
AU - Kalos, T.
AU - Soulaidopoulos, S.
AU - Lazarou, E.
AU - Vlachopoulos, C.
AU - Vassilopoulos, D.
AU - Tsakris, A.
AU - Tsioufis, C.
JO - Vaccine
PY - 2021
VL - 39
TODO - 45
SP - 6585-6590
PB - ELSEVIER SCIENCE LTD.
SN - 0264-410X
TODO - 10.1016/j.vaccine.2021.09.078
TODO - ad26.cov2.s vaccine;  comirnaty;  elasomeran;  vaxzevria;  bnt 162 vaccine;  ChAdOx1 COVID-19 vaccine, adult;  aged;  aging;  Article;  clinical article;  cohort analysis;  coronavirus disease 2019;  disease course;  drug safety;  Europe;  female;  heart tamponade;  hospitalization;  human;  male;  middle aged;  pericardial decompression;  pericardial disease;  pericarditis;  practice guideline;  sex ratio;  thorax pain;  United States;  adverse event;  pericarditis;  vaccination, Aged;  COVID-19;  COVID-19 Vaccines;  Europe;  Female;  Humans;  Male;  Middle Aged;  Pericarditis;  SARS-CoV-2;  United States;  Vaccination
TODO - Background: COVID-19 vaccines were efficacious and safe in clinical trials. We report nine events of acute pericarditis (AP) in eight patients following COVID-19 vaccination with BNT162b2 (6/9), AZD1222 (2/9) and mRNA-1273 (1/9). Methods: All patients were referred for AP temporally linked with COVID-19 vaccination. Chest pain was the most common clinical manifestation. Alternative etiologies were excluded upon thorough diagnostic work up. AP diagnosis was established according to ESC guidelines. Findings: Five events occurred after the first vaccine dose and four after the second. The mean age in this cohort was 65.8 ± 10.2 years and the men/women ratio 3/5. All events resolved without sequelae; two events were complicated by cardiac tamponade requiring emergent pericardial decompression. Hospitalization was required in four cases. Interpretation: Although causality cannot be firmly established, AP has emerged as a possible complication following COVID-19 vaccination. Further investigation is indispensable to fully characterize this new entity. © 2021 Elsevier Ltd
ER -